Delving into the Latest Updates on Cytochlor with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cld/Cyd, CldC

Target-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesMouth and Tooth Diseases+ [1]

Active Indication-

Inactive Indication

Advanced Head and Neck Squamous Cell CarcinomaBrain metastasesSquamous cell carcinoma of the oral cavity

Originator Organization

University of Miami

Active Organization-

Inactive Organization

National Cancer Institute

University of Miami

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC9H12ClN3O4

InChIKeyNGGRGTWYSXYVDK-RRKCRQDMSA-N

CAS Registry32387-56-7

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy.
PURPOSE: This phase I trial is studying the side effects and best dose of cytochlor when given together with tetrahydrouridine and external-beam radiation therapy in treating patients with cancer that has spread to the brain.

Start Date01 Jun 2007

Sponsor / Collaborator

University of Miami

NCT00077051 / CompletedPhase 1IIT

Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With a Fixed Dose of Cisplatin Concomitant With Definitive Radiation in Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity and Oropharynx

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiosensitizing drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as cisplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Combining radiosensitizers with chemotherapy and radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of cytochlor when given together with tetrahydrouridine, cisplatin and radiation therapy in treating patients with advanced squamous cell carcinoma of the oral cavity (mouth) or oropharynx (throat).

Start Date01 Apr 2004

Sponsor / Collaborator

University of Miami

[+1]

100 Clinical Results associated with Cytochlor

Login to view more data

100 Translational Medicine associated with Cytochlor

Login to view more data

100 Patents (Medical) associated with Cytochlor

Login to view more data

39

Literatures (Medical) associated with Cytochlor

01 Sep 2023·Transplantation Proceedings

Long-Term Feasibility of Rescue Reconstruction for Isolated Bile Ducts With Using Cystic Duct in Living Donor Liver Transplantation

Article

Author: Akita, Hirofumi ; Iwagami, Yoshifumi ; Eguchi, Hidetoshi ; Takahashi, Hidenori ; Nagano, Hiroaki ; Dono, Keizo ; Marukawa, Daiki ; Gotoh, Kunihito ; Yamada, Daisaku ; Marubashi, Shigeru ; Sasaki, Kazuki ; Asaoka, Tadafumi ; Tomimaru, Yoshito ; Noda, Takehiro ; Kubo, Masahiko ; Kobayashi, Shogo ; Doki, Yuichiro ; Tanemura, Masahiro

BACKGROUNDThe isolated bile duct is sometimes observed in the right liver graft of living donor liver transplantation (LDLT). Even though, as a rescue option, it is known to use the recipient's cystic duct (CyD) for duct-to-duct anastomosis, the long-term feasibility of rescue duct-to-CyD (D-CyD) anastomosis remains unclear.METHODSWe prospectively collected data in the right liver-LDLT cohort and compared rescue D-CyD anastomosis (n = 4) with standard duct-to-hepatic duct (D-HD, n = 45) anastomosis (D-CyD group, n = 4).RESULTSThe observation period was over 5 years (range, 68-171 mo) after LDLT. The D-CyD group included the following anastomosis procedures: anastomosis between the intrahepatic bile duct of the graft and the CyD of the recipient and anastomosis between the posterior HD and the CyD. Surgical outcomes between the 2 groups are similar, excluding the time for the biliary reconstruction (D-CyD, 116 ± 13 min vs D-HD, 57 ± 3 min). During the period, one recipient in the D-CyD group exhibited postoperative biliary stricture and biliary stone, and 6 recipients underwent those complications in the D-HD group (D-CyD, 25.0% vs D-HD, 13.3%) All recipients in the D-CyD group are presently alive and have not experienced liver dysfunction.CONCLUSIONSOur findings suggest that rescue D-CyD anastomosis for an isolated bile duct in a right liver LDLT is acceptable as a life-saving option in terms of long-term feasibility.

14 Aug 2018·The Journal of Infectious DiseasesQ2 · MEDICINE

A Lipid/DNA Adjuvant–Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge

Q2 · MEDICINE

Article

Author: Miller, Christopher J ; Jegaskanda, Sinthujan ; Fairman, Jeffery ; Fritts, Linda ; Matzinger, Shannon R ; McChesney, Michael B ; Carroll, Timothy D ; Kent, Stephen J

BackgroundInfluenza A virus (IAV) vaccines offer little protection from mismatched viruses with antigenically distant hemagglutinin (HA) glycoproteins. We sought to determine if a cationic lipid/DNA complex (CLDC) adjuvant could induce heterosubtypic protection if added to a whole inactivated IAV vaccine (WIV).MethodsAdult rhesus macaques (RMs) were vaccinated and at 2 weeks boosted with either an H1N1-WIV or an H3N2-WIV, with and without CLDC adjuvant. Four weeks postboost, animals were challenged with an H1N1 IAV matched to the H1N1-WIV vaccine.ResultsAfter challenge, viral RNA (vRNA) levels in the trachea of control RMs and RMs vaccinated with the unadjuvanted H1 or H3 WIV vaccines were similar. However, vRNA levels in the trachea of both the H1-WIV/CLDC- and the H3-WIV/CLDC-vaccinated RMs (P < 0.01 and P < 0.05, respectively) were significantly lower than in unvaccinated control RMs. Heterosubtypic protection in H3-WIV/CLDC RMs was associated with significantly higher levels of nucleoprotein (NP) and matrix-1-specific immunoglobulin G antibodies (P < 0.05) and NP-specific nonneutralizing antibody-dependent natural killer cell activation (P < 0.01) compared with unprotected H3-WIV RMs.ConclusionsAddition of the CLDC adjuvant to a simple WIV elicited immunity to conserved virus structural proteins in RMs that correlate with protection from uncontrolled virus replication after heterosubtypic influenza virus challenge.

01 Dec 2017·VaccineQ3 · MEDICINE

Immunization against full-length protein and peptides from the Lutzomyia longipalpis sand fly salivary component maxadilan protects against Leishmania major infection in a murine model

Q3 · MEDICINE

Article

Author: Arthun, Erik N ; Spencer, John S ; Wheat, William H ; Regan, Daniel P ; Titus, Richard G ; Dow, Steven W

Leishmaniasis is an arthropod vectored disease causing considerable human morbidity and mortality. Vaccination remains the most realistic and practical means to interrupt the growing number and diversity of sand fly vectors and reservoirs of Leishmania. Since transmission of Leishmania is achieved exclusively by sand fly vectors via immune-modulating salivary substances, conventional vaccination requiring an unmodified host immune response for success are potentially destined to fail unless immunomodulatory factors are somehow neutralized. Using cationic liposome DNA complexes (CLDC) as an adjuvant system along with Lu. longipalpis sand fly salivary component maxadilan (MAX) as antigen (Ag), we show that mice are protected from the MAX-induced exacerbation of infection with Leishmania major (Lm). The CLDC adjuvant and alum were comparable in terms of lesion induration and decreased parasite burden, however the alum adjuvant imposed more inflammation at the injection site. BALB/c, C3H and C57BL/6 mice vaccinated with MAX-CLDC containing either the full-length MAX or peptides spanning the N- and C-terminal regions of MAX are protected against footpad challenges with Lm co-injected with MAX. When compared to unvaccinated controls, all strains of mice immunized with CLDC containing either peptides encompassing the first 20 N-terminal AA or those spanning the last 15 AA of the C-terminal domain of MAX demonstrated decreased parasite burden after 9 or 18 weeks post challenge with Lm + MAX. MAX-CLDC immunized mice showed increased IFNγ-secreting and decreased IL-4-secreting CD4⁺ cells in footpad-draining lymph nodes. Antisera from C-terminal peptide (P11) MAX-CLDC-vaccinated animals was capable of recognizing FL-MAX and its C-terminal domain and also blocked MAX-mediated reprogramming of bone marrow-derived dendritic cells (BM-DC) in vitro. This peptide vaccine targeting sand fly MAX, improves host immunity against MAX-mediated immunomodulation.

100 Deals associated with Cytochlor

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12383

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain metastases	Phase 1	US	University of Miami	01 Jun 2007
Advanced Head and Neck Squamous Cell Carcinoma	Phase 1	US	National Cancer Institute	01 Apr 2004
Squamous cell carcinoma of the oral cavity	Phase 1	US	National Cancer Institute	01 Apr 2004